Nuvalent (NASDAQ:NUVL) Downgraded by Barclays to Hold

Nuvalent (NASDAQ:NUVL) was downgraded by analysts at Barclays from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvalent in a report on Tuesday, April 21st. Truist Financial set a $124.00 target price on Nuvalent in a report on Tuesday. Cantor Fitzgerald cut Nuvalent from an “overweight” rating to a “neutral” rating in a report on Tuesday. HC Wainwright downgraded shares of Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 price objective for the company. in a research note on Tuesday. Finally, UBS Group downgraded shares of Nuvalent from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $138.00 to $124.00 in a research note on Wednesday. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Nuvalent has an average rating of “Hold” and a consensus price target of $131.15.

Nuvalent Trading Up 0.1%

NUVL stock opened at $123.35 on Tuesday. The stock has a 50-day moving average price of $103.44 and a two-hundred day moving average price of $103.19. The stock has a market cap of $9.74 billion, a PE ratio of -20.35 and a beta of 1.15. Nuvalent has a 1 year low of $71.13 and a 1 year high of $123.62.

Nuvalent (NASDAQ:NUVL) last released its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period in the previous year, the company posted ($1.18) earnings per share. On average, analysts forecast that Nuvalent will post -5.74 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Henry E. Pelish sold 3,093 shares of Nuvalent stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $104.48, for a total value of $323,156.64. Following the transaction, the insider directly owned 65,604 shares of the company’s stock, valued at $6,854,305.92. This trade represents a 4.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Deborah Ann Miller sold 5,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $107.84, for a total transaction of $593,120.00. Following the completion of the sale, the insider owned 59,634 shares in the company, valued at $6,430,930.56. This represents a 8.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 126,953 shares of company stock valued at $12,612,264. 5.02% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after acquiring an additional 108 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Nuvalent by 1.5% in the 4th quarter. Kennedy Capital Management LLC now owns 10,932 shares of the company’s stock worth $1,100,000 after buying an additional 163 shares during the last quarter. US Bancorp DE increased its holdings in shares of Nuvalent by 10.0% in the 3rd quarter. US Bancorp DE now owns 2,070 shares of the company’s stock worth $179,000 after buying an additional 188 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Nuvalent by 141.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after purchasing an additional 195 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in Nuvalent by 7.7% during the 3rd quarter. Principal Financial Group Inc. now owns 3,290 shares of the company’s stock valued at $285,000 after buying an additional 234 shares during the period. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s all-cash acquisition offer values Nuvalent at roughly $10.6 billion and implies a meaningful premium to recent trading levels, giving shareholders a clear exit price. Reuters article on GSK deal
• Positive Sentiment: Analysts and market commentary suggest the deal makes strategic sense for GSK because Nuvalent brings a late-stage lung cancer pipeline, reinforcing investor confidence that the transaction is real and financially significant. WSJ article on GSK deal
• Neutral Sentiment: Several law firms have launched investigations into whether the sale process and $124.00 price are fair to shareholders, which could create some headline noise but does not change the announced deal terms yet. Business Wire article on investigation
• Neutral Sentiment: Wells Fargo and other brokers trimmed ratings after the takeover announcement, but their updated price targets remain near the deal value, so these moves are unlikely to outweigh the acquisition news. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, which may slightly pressure sentiment by reinforcing that insiders have been reducing exposure ahead of the transaction. SEC insider filing

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.